이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
CytomX Therapeutics 미래 성장
Future 기준 확인 0/6
CytomX Therapeutics 의 수익과 수익은 각각 연간 15.2% 및 27.2% 감소할 것으로 예상됩니다. EPS는 연간 26.1% 만큼 쇠퇴할 것으로 예상됩니다.
주요 정보
-27.9%
수익 성장률
-28.8%
EPS 성장률
| Biotechs 수익 성장 | 28.5% |
| 매출 성장률 | -15.2% |
| 향후 자기자본 수익률 | n/a |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 13 Sep 2024 |
최근 미래 성장 업데이트
Recent updates
CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments
Jul 15The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
Jun 15
We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now
May 09CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling
May 02CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 27CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Apr 25CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%
Mar 05CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Jan 19There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise
Nov 26We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 29Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%
Nov 10CytomX Therapeutics to cut workforce by about 40%
Jul 13CytomX says phase 2 study of breast cancer antibody treatment met main goal
Jul 06Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10CytomX: Pullbacks Are Opportunities
Dec 14CytomX: Solving A Critical Problem In The High-Value ADC Space
Sep 15We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
Aug 11Checking In On CytomX Therapeutics
Jun 13수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2026 | 67 | -57 | -37 | N/A | 2 |
| 12/31/2025 | 73 | -59 | -40 | -66 | 5 |
| 12/31/2024 | 100 | -27 | -44 | -65 | 6 |
| 6/30/2024 | 120 | 11 | -86 | -86 | N/A |
| 3/31/2024 | 119 | 17 | -92 | -91 | N/A |
| 12/31/2023 | 101 | -1 | -57 | -56 | N/A |
| 9/30/2023 | 95 | -10 | -36 | -35 | N/A |
| 6/30/2023 | 79 | -42 | -52 | -51 | N/A |
| 3/31/2023 | 68 | -71 | -61 | -60 | N/A |
| 12/31/2022 | 53 | -99 | -113 | -111 | N/A |
| 9/30/2022 | 21 | -149 | -142 | -141 | N/A |
| 6/30/2022 | 27 | -143 | -138 | -136 | N/A |
| 3/31/2022 | 30 | -132 | -132 | -130 | N/A |
| 12/31/2021 | 37 | -116 | -121 | -119 | N/A |
| 9/30/2021 | 66 | -72 | -107 | -105 | N/A |
| 6/30/2021 | 66 | -64 | -103 | -100 | N/A |
| 3/31/2021 | 67 | -61 | 23 | 25 | N/A |
| 12/31/2020 | 68 | -65 | 3 | 5 | N/A |
| 9/30/2020 | 92 | -54 | -9 | -7 | N/A |
| 6/30/2020 | 85 | -63 | -8 | -5 | N/A |
| 3/31/2020 | 78 | -76 | -154 | -151 | N/A |
| 12/31/2019 | 27 | -133 | -144 | -140 | N/A |
| 9/30/2019 | 61 | -99 | -144 | -140 | N/A |
| 6/30/2019 | 62 | -99 | -126 | -122 | N/A |
| 3/31/2019 | 75 | -83 | -105 | -100 | N/A |
| 12/31/2018 | 60 | -85 | -79 | -76 | N/A |
| 9/30/2018 | 75 | -52 | -28 | -25 | N/A |
| 6/30/2018 | 87 | -39 | -27 | -25 | N/A |
| 3/31/2018 | 74 | -50 | N/A | 175 | N/A |
| 12/31/2017 | 72 | -43 | N/A | 170 | N/A |
| 9/30/2017 | 51 | -58 | N/A | 150 | N/A |
| 6/30/2017 | 30 | -62 | N/A | 142 | N/A |
| 3/31/2017 | 24 | -51 | N/A | -16 | N/A |
| 12/31/2016 | 15 | -59 | N/A | -2 | N/A |
| 9/30/2016 | 11 | -57 | N/A | -12 | N/A |
| 6/30/2016 | 9 | -57 | N/A | -6 | N/A |
| 3/31/2016 | 8 | -50 | N/A | -28 | N/A |
| 12/31/2015 | 8 | -42 | N/A | -27 | N/A |
| 9/30/2015 | 8 | -36 | N/A | -24 | N/A |
| 6/30/2015 | 8 | -26 | N/A | 30 | N/A |
| 3/31/2015 | 6 | -24 | N/A | 31 | N/A |
| 12/31/2014 | 5 | -35 | N/A | 32 | N/A |
| 12/31/2013 | 1 | -19 | N/A | -8 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: CTMX 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -27.2% ).
수익 vs 시장: CTMX 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -27.2% ).
고성장 수익: CTMX 의 수익은 향후 3년간 감소할 것으로 예상됩니다.
수익 대 시장: CTMX 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -15.2% ).
고성장 수익: CTMX 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -15.2% ).
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: CTMX 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.